Quick answers
- What is Elacestrant used for?
- The FDA-approved label (Orserdu, Stemline Therapeutics, Inc., June 24, 2026) says: “ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test […], with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Elacestrant have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Elacestrant?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Elacestrant been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Elacestrant?
- 1 company lists prescription products of Elacestrant in the FDA NDC Directory, including Stemline Therapeutics, Inc..
What Elacestrant is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test […], with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for …
— FDA label: Orserdu, Stemline Therapeutics, Inc., effective June 24, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Orserdu |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Stemline Therapeutics, Inc.2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA217639 ORSERDU | Stemline Therap | January 27, 2023 | 2, latest June 24, 2026 2026: Labeling · 2023: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2628478, 2628484, 2628487, 2628489 |
|---|---|
| SPL set ID of the quoted label | aa66ae5c-2bd2-4444-8178-b55651e054ef |
| FDA labels (SPL) | 1 |
| FDA applications | NDA217639 |
| Active ingredients (FDA) | ELACESTRANT |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Orserdu, Stemline Therapeutics, Inc., effective June 24, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →